Industry Events
EnglishFrançaisEspañol中文العربية
活动新闻行业洞察主办方
服务
  • 活动营销向全球B2B受众发布、推广并拓展您的活动。
  • 新闻稿向全球行业专业人士分发官方公告。
  • 演讲者与专家推广展示您的专业知识,获得主旨演讲、专题讨论和大师班邀约。
订阅
演讲者登录免费发布您的活动
Industry Events

全球最值得信赖的B2B活动发现平台。将行业专业人士与重要的会议、展会和峰会连接起来。

  • Industry Events
  • 新闻
  • 活动主办方
  • 关于我们
  • 我们的服务
  • 高级主办方
  • Event Pro
  • 成为演讲者
  • 订阅
  • 使用条款
  • 隐私政策

© 2026 Industry Events Worldwide。保留所有权利。

VF96.7.
  • 活动
  • 新闻
  • 行业洞察
  • 账户
Industry Events
EnglishFrançaisEspañol中文العربية
活动新闻行业洞察主办方
服务
  • 活动营销向全球B2B受众发布、推广并拓展您的活动。
  • 新闻稿向全球行业专业人士分发官方公告。
  • 演讲者与专家推广展示您的专业知识,获得主旨演讲、专题讨论和大师班邀约。
订阅
演讲者登录免费发布您的活动
Industry Events

News

Categories

  • 最新
  • 中国与金砖国家+
  • 人工智能与科技
  • 供应链
  • 农业
  • 创业与风险投资
  • 医疗健康
  • 半导体
  • 国防
  • 机器人
  • 网络安全
  • 能源与出行
  • 金融科技

Select a category to explore the latest industry reporting.

NewsTuesday, 25 August 2026
Newsletter subscribe · Free
  • 最新
  • 人工智能与科技
  • 网络安全
  • 半导体
  • 机器人
  • 金融科技
  • 能源与出行
  • 国防
  • 医疗健康
  • 供应链
  • 创业与风险投资
  • 中国与金砖国家+
  • 农业

新闻

医疗健康

来自塑造行业的会议、展会和峰会的 医疗健康 领域最新新闻、公告和分析。

该分类的最新新闻

STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more (opens original source in a new tab)
STAT News

STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

Industry Events

全球最值得信赖的B2B活动发现平台。将行业专业人士与重要的会议、展会和峰会连接起来。

The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis

(opens original source in a new tab)
Ed Silverman·11 August 2026
STAT+: A RAPID proposal for breakthrough coverage, and nurses push back on AI (opens original source in a new tab)
STAT News

STAT+: A RAPID proposal for breakthrough coverage, and nurses push back on AI

In this edition of STAT Health Tech: Details from CMS and FDA on the RAPID pathway for breakthrough devices, and nurses push back on AI.

(opens original source in a new tab)
Katie Palmer·11 August 2026
STAT+: Skylark Bio kicks off new gene therapy trial for deafness (opens original source in a new tab)
STAT News

STAT+: Skylark Bio kicks off new gene therapy trial for deafness

Biotech startups in the U.S., France, and China are racing to bring new gene therapies for deafness by targeting different genetic mutations.

(opens original source in a new tab)
O. Rose Broderick·11 August 2026
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate? (opens original source in a new tab)
STAT News

STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?

Biotech companies don’t hide or obfuscate strong data.

(opens original source in a new tab)
Adam Feuerstein·11 August 2026
Trump returns to controversial vaccine policy with order questioning childhood schedule (opens original source in a new tab)
STAT News

Trump returns to controversial vaccine policy with order questioning childhood schedule

The Trump administration, which had recently avoided public discussions of vaccine policy because of concern around the political repercussions, is changing course.

(opens original source in a new tab)
Daniel Payne·10 August 2026
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment (opens original source in a new tab)
STAT News

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

(opens original source in a new tab)
Allison DeAngelis·10 August 2026
FDA to require notice of additives in food supply for the first time (opens original source in a new tab)
STAT News

FDA to require notice of additives in food supply for the first time

RFK Jr. is claiming a win with a new proposal on the food industry's GRAS loophole; nutrition advocates give mixed reviews.

(opens original source in a new tab)
Isabella Cueto and Elizabeth Cooney·10 August 2026
STAT+: Ban prior auth? And hospitals cut jobs (opens original source in a new tab)
STAT News

STAT+: Ban prior auth? And hospitals cut jobs

We examine a call to reform how health insurers do business, and a look at the impact of 340B restrictions.

(opens original source in a new tab)
Bob Herman·10 August 2026
STAT+: FDA panel to weigh Grail’s Galleri test (opens original source in a new tab)
STAT News

STAT+: FDA panel to weigh Grail’s Galleri test

China reins in its biotech innovation engine, radiopharma boom meets unexpected hurdles, and more news from The Readout

(opens original source in a new tab)
Meghana Keshavan·10 August 2026
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more (opens original source in a new tab)
STAT News

STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more

Sanofi is experiencing shortages of two medicines used to treat Pompe disease after the FDA warned the company over manufacturing issues

(opens original source in a new tab)
Ed Silverman·10 August 2026
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial (opens original source in a new tab)
STAT News

STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.

(opens original source in a new tab)
Jason Mast·10 August 2026
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study (opens original source in a new tab)
STAT News

STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study

A Tenax Therapeutics drug designed to treat a type of heart failure associated with high blood pressure in the lungs failed in a closely watched study.

(opens original source in a new tab)
Adam Feuerstein·10 August 2026

最多阅读

  1. 01

    STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

  2. 02

    STAT+: A RAPID proposal for breakthrough coverage, and nurses push back on AI

  3. 03

    STAT+: Skylark Bio kicks off new gene therapy trial for deafness

  4. 04

    STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?

  5. 05

    Trump returns to controversial vaccine policy with order questioning childhood schedule

Prev
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
Next
  • Industry Events
  • 新闻
  • 活动主办方
  • 关于我们
  • 我们的服务
  • 高级主办方
  • Event Pro
  • 成为演讲者
  • 订阅
  • 使用条款
  • 隐私政策

© 2026 Industry Events Worldwide。保留所有权利。

VF96.7.

每周五送达的行业活动一周要闻。

一封简短的邮件。汇集塑造全球商业的展会、会议和峰会的头条新闻。没有废话,没有垃圾邮件,随时可取消订阅。